Response Criteria in Advanced Systemic Mastocytosis: Evolution in the Era of KIT Inhibitors

por Shomali, William, Gotlib, Jason
Publicado 2021

Intensive Serial Biomarker Profiling for the Prediction of Neutropenic Fever in Patients with Hematologic Malignancies Undergoing Chemotherapy: A Pilot Study

por Chan, Steven M., Chadwick, John, Young, Daniel L., Holmes, Elizabeth, Gotlib, Jason
Publicado 2014

Sustained Complete Molecular Remission With Imatinib Monotherapy in a Child Presenting With Blast Phase FIP1L1-PDGFRA-Associated Myeloid Neoplasm With Eosinophilia

por Jain, Juhi, Weinzierl, Elizabeth P., Saxe, Debra, Bergsagel, John, Gotlib, Jason, Reiter, Andreas, Raikar, Sunil S.
Publicado 2020

Intricate and Cell Type-Specific Populations of Endogenous Circular DNA (eccDNA) in Caenorhabditis elegans and Homo sapiens

por Shoura, Massa J., Gabdank, Idan, Hansen, Loren, Merker, Jason, Gotlib, Jason, Levene, Stephen D., Fire, Andrew Z.
Publicado 2017

Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis

por Jamieson, Catriona, Hasserjian, Robert, Gotlib, Jason, Cortes, Jorge, Stone, Richard, Talpaz, Moshe, Thiele, Jürgen, Rodig, Scott, Pozdnyakova, Olga
Publicado 2015

Platelet transcriptome identifies progressive markers and potential therapeutic targets in chronic myeloproliferative neoplasms

por Shen, Zhu, Du, Wenfei, Perkins, Cecelia, Fechter, Lenn, Natu, Vanita, Maecker, Holden, Rowley, Jesse, Gotlib, Jason, Zehnder, James, Krishnan, Anandi
Publicado 2021

Enkurin: a novel marker for myeloproliferative neoplasms from platelet, megakaryocyte, and whole blood specimens

por Seetharam, Sumanth Mosale, Liu, Yi, Wu, Jason, Fechter, Lenn, Murugesan, Kanagavel, Maecker, Holden, Gotlib, Jason, Zehnder, James, Paulmurugan, Ramasamy, Krishnan, Anandi
Publicado 2023

Enkurin: A novel marker for myeloproliferative neoplasms from platelet, megakaryocyte, and whole blood specimens

por Mosale Seetharam, Sumanth, Liu, Yi, Wu, Jason, Fechter, Lenn, Murugesan, Kanagavel, Maecker, Holden, Gotlib, Jason, Zehnder, James, Paulmurugan, Ramasamy, Krishnan, Anandi
Publicado 2023

Comprehensive response criteria for myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: a proposal from the MLN International Working Group

por Shomali, William, Colucci, Philomena, George, Tracy I., Kiladjian, Jean-Jacques, Langford, Cheryl, Patel, Jay L., Reiter, Andreas, Vannucchi, Alessandro M., Gotlib, Jason
Publicado 2023

Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes

por Verstovsek, Srdan, Gotlib, Jason, Gupta, Vikas, Atallah, Ehab, Mascarenhas, John, Quintas-Cardama, Alfonso, Sun, William, Sarlis, Nicholas J, Sandor, Victor, Levy, Richard S, Kantarjian, Hagop M, Mesa, Ruben A
Publicado 2013

Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses

por Verstovsek, Srdan, Gotlib, Jason, Mesa, Ruben A., Vannucchi, Alessandro M., Kiladjian, Jean-Jacques, Cervantes, Francisco, Harrison, Claire N., Paquette, Ronald, Sun, William, Naim, Ahmad, Langmuir, Peter, Dong, Tuochuan, Gopalakrishna, Prashanth, Gupta, Vikas
Publicado 2017

Altered translation of GATA1 in Diamond-Blackfan anemia

por Ludwig, Leif S., Gazda, Hanna T., Eng, Jennifer C., Eichhorn, Stephen W., Thiru, Prathapan, Ghazvinian, Roxanne, George, Tracy I., Gotlib, Jason R., Beggs, Alan H., Sieff, Colin A., Lodish, Harvey F., Lander, Eric S., Sankaran, Vijay G.
Publicado 2014

P1022: PHASE 1/2 STUDY OF THE ACTIVIN RECEPTOR-LIKE KINASE 2 (ALK2) INHIBITOR ZILURGISERTIB (INCB000928, LIMBER-104) AS MONOTHERAPY OR WITH RUXOLITINIB IN PATIENTS WITH ANEMIA DUE...

por Bose, Prithviraj, Mohan, Sanjay, Oh, Stephen, Gotlib, Jason, Ritchie, Ellen, Shimomura, Taizo, Ali, Haris, Boyer, Francoise, Guglielmelli, Paola, Hunter, Anthony M., Lamothe, Betty, Cui, Yi, Seguy, Francis, Mcbride, Amanda, Palandri, Francesca, Takeuchi, Masahiro, Kiladjian, Jean-Jacques
Publicado 2023

European LeukemiaNet Response Predicts Disease Progression but Not Thrombosis in Polycythemia Vera

por Tremblay, Douglas, Srisuwananukorn, Andrew, Ronner, Lukas, Podoltsev, Nikolai, Gotlib, Jason, Heaney, Mark L., Kuykendall, Andrew, O’Connell, Casey L., Shammo, Jamile M., Fleischman, Angela, Mesa, Ruben, Yacoub, Abdulraheem, Hoffman, Ronald, Moshier, Erin, Zubizarreta, Nicole, Mascarenhas, John
Publicado 2022

Tuning MPL signaling to influence hematopoietic stem cell differentiation and inhibit essential thrombocythemia progenitors

por Cui, Lu, Moraga, Ignacio, Lerbs, Tristan, Van Neste, Camille, Wilmes, Stephan, Tsutsumi, Naotaka, Trotman-Grant, Aaron Claudius, Gakovic, Milica, Andrews, Sarah, Gotlib, Jason, Darmanis, Spyros, Enge, Martin, Quake, Stephen, Hitchcock, Ian S., Piehler, Jacob, Garcia, K. Christopher, Wernig, Gerlinde
Publicado 2021

S167: EFFICACY AND SAFETY OF LUSPATERCEPT FOR THE TREATMENT OF ANEMIA IN PATIENTS WITH MYELOFIBROSIS: RESULTS FROM THE ACE-536-MF-001 STUDY

por Gerds, Aaron T., Harrison, Claire, Kiladjian, Jean-Jacques, Mesa, Ruben, Vannucchi, Alessandro, Komrokji, Rami S., Bose, Prithviraj, Kremyanskaya, Marina, Mead, Adam, Gotlib, Jason, Sanabria, Fabian, Marsousi, Niloufar, Giuseppi, Ana Carolina, Jiang, Huijing, Palmer, Jeanne, Mccaul, Kelly, Ribrag, Vincent, Verstovsek, Srdan, Passamonti, Francesco
Publicado 2023

Whole-genome CRISPR screening identifies N-glycosylation as a genetic and therapeutic vulnerability in CALR-mutant MPNs

por Jutzi, Jonas S., Marneth, Anna E., Ciboddo, Michele, Guerra-Moreno, Angel, Jiménez-Santos, María José, Kosmidou, Anastasia, Dressman, James W., Liang, Hongyan, Hamel, Rebecca, Lozano, Patricia, Rumi, Elisa, Doench, John G., Gotlib, Jason, Krishnan, Anandi, Elf, Shannon, Al-Shahrour, Fátima, Mullally, Ann
Publicado 2022

Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trial

por Verstovsek, Srdan, Foltz, Lynda, Gupta, Vikas, Hasserjian, Robert, Manshouri, Taghi, Mascarenhas, John, Mesa, Ruben, Pozdnyakova, Olga, Ritchie, Ellen, Veletic, Ivo, Gamel, Katia, Hamidi, Habib, Han, Lyrialle, Higgins, Brian, Trunzer, Kerstin, Uguen, Marianne, Wang, Dao, El-Galaly, Tarec Christoffer, Todorov, Boyan, Gotlib, Jason
Publicado 2023

Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis

por Reiter, Andreas, Schwaab, Juliana, DeAngelo, Daniel J., Gotlib, Jason, Deininger, Michael W., Pettit, Kristen M., Alvarez-Twose, Iván, Vannucchi, Alessandro M., Panse, Jens, Platzbecker, Uwe, Hermine, Olivier, Dybedal, Ingunn, Lin, Hui-Min, Rylova, Svetlana N., Ehlert, Katrin, Dimitrijević, Saša, Radia, Deepti H.
Publicado 2022

P1023: AVAPRITINIB IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS (ADVSM): EFFICACY AND SAFETY ANALYSES FROM THE PHASE 2 PATHFINDER STUDY WITH 2-YEAR FOLLOW-UP

por Gotlib, Jason, Reiter, Andreas, Radia, Deepti, Deininger, Michael, George, Tracy, Panse, Jens, Vannucchi, Alessandro, Platzbecker, Uwe, Alvarez-Twose, Ivan, Mital, Andrzej, Hermine, Olivier, Dybedal, Ingunn, Hexner, Elizabeth O., Span, Lambert, Mesa, Ruben, Bose, Prithviraj, Pettit, Kirsten, Oh, Stephen, Lin, Hui-Min, Dimitrijevic, Sasa, Muñoz-González, Javier, Deangelo, Daniel J.
Publicado 2023